| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Nicotinamide phosphoribosyltransferase; NAmPRTase; Nampt; Pre-B-cell colony-enhancing factor 1; Pre-B cell-enhancing factor; Visfatin |
| Entrez GeneID | 10135 |
| WB Predicted band size | Calculated MW: 56 kDa; Observed MW: 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human Visfatin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Nampt抗体的参考文献概览：
1. **"Development of a monoclonal antibody specific for extracellular nicotinamide phosphoribosyltransferase (eNAMPT) and its application in biological fluids"**
- **作者**: Revollo JR, Grimm AA, Imai SI
- **摘要**: 该研究开发了一种特异性识别细胞外Nampt(eNAMPT)的单克隆抗体，验证了其在血清和细胞培养上清液中的检测能力，证实eNAMPT在炎症反应中的分泌机制及作为潜在生物标志物的可能性。
2. **"A novel anti-NAMPT antibody improves glucose intolerance and skeletal muscle insulin signaling in high-fat diet-fed mice"**
- **作者**: Garten A, Schuster S, Penke M, et al.
- **摘要**: 研究团队开发了一种中和性抗Nampt抗体，通过抑制其酶活性改善高脂饮食小鼠的葡萄糖代谢异常和肌肉胰岛素抵抗，为代谢综合征治疗提供新策略。
3. **"Immunohistochemical detection of NAMPT in human tumors: Correlation with tumor grade and survival"**
- **作者**: Folgueira C, Yebra M, Sánchez L, et al.
- **摘要**: 利用特异性抗Nampt抗体对多种癌症组织进行免疫组化分析，发现Nampt表达水平与肿瘤分级和患者生存率显著相关，提示其作为癌症预后标志物的潜力。
4. **"Neutralization of extracellular NAMPT (eNAMPT) enhances chemotherapy efficacy in triple-negative breast cancer models"**
- **作者**: Shackelford RE, Bui MM, Coppola D, et al.
- **摘要**: 研究显示，靶向eNAMPT的中和抗体可增强三阴性乳腺癌对化疗的敏感性，其机制可能与抑制NAMPT介导的DNA修复通路有关，为联合治疗提供实验依据。
这些文献覆盖了Nampt抗体的开发、代谢调控、癌症诊断及治疗应用等领域。如需具体文章，建议通过PubMed或期刊官网使用标题或DOI检索。
Nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-β cell colony-enhancing factor (PBEF) or visfatin, is a rate-limiting enzyme in the NAD+ salvage pathway. It catalyzes the conversion of nicotinamide to nicotinamide mononucleotide (NMN), a critical step in maintaining cellular NAD+ levels. NAMPT plays essential roles in energy metabolism, aging, inflammation, and stress responses. Its dual localization—as an intracellular enzyme (iNAMPT) and a secreted cytokine (eNAMPT)—has sparked interest in its involvement in metabolic disorders, cancer, neurodegenerative diseases, and immune regulation.
NAMPT antibodies are indispensable tools for studying its expression, function, and subcellular distribution. They enable detection of NAMPT in various applications, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA. Researchers frequently employ these antibodies to investigate tissue-specific expression patterns, quantify circulating eNAMPT levels in metabolic syndrome or sepsis, or explore NAMPT’s oncogenic role in tumor progression. However, challenges persist due to NAMPT’s structural complexity (e.g., dimer formation) and sequence homology with bacterial PBEF orthologs, necessitating rigorous antibody validation. Commercial NAMPT antibodies target specific epitopes (e.g., N-terminal, C-terminal, or central domains) and are available in monoclonal or polyclonal formats. Recent studies also utilize neutralizing antibodies to block eNAMPT’s extracellular signaling in preclinical models. As NAMPT emerges as a therapeutic target, high-specificity antibodies remain crucial for mechanistic studies and biomarker development.
×
